Wang FT, Green E, Mines D, Mehta V, Lin ND. A study to assess the capture of sublingual immunotherapy within an electronic health record (EHR) system. Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2018. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2018 Aug; 25(S3):395-6.
Wang T, Liu Z, Mines D. Adding of CPT codes improves classification of type of bowel resection based only on ICD-9-CM procedure codes. Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2018. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2018 Aug; 25(S3):162.
Fortuny J, Rasouliyan L, Mines D, Tormos A, Earley E, Perez-Gutthann S, Domenech E, Gisbert JP. Characterization of patients with ulcerative colitis in a post-authorization safety study of golimumab based in the Spanish ENEIDA Registry. Poster presented at the 34th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 24, 2018. Prague, Czech Republic. [abstract] Pharmacoepidemiol Drug Saf. 2018 Aug; 27(S2):47. doi: 10.1002/pds.4629
Bongartz T, Warren FC, Mines D, Matteson EL, Abrams KR, Sutton AJ. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Presented at the 2008 Annual Meeting of the American College of Rheumatology; October 2008. San Francisco, CA. [abstract] Arthritis Rheum. 2008 Sep; 58(9 Suppl):S782.
Cooper G, Mines D, Gu Y. Recombinant human bone morphogenetic protein-2 and pancreatic cancer: a retrospective cohort study. Presented at the 24th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; 2008. Copenhagen, Denmark. [abstract] Pharmacoepidemiol Drug Saf. 2008 Aug; 17(S1):S110-1.
Umscheid CA, Maguire MG, Pines JM, Everett WW, Baren JM, Townsend RR, Mines D, Szyld D, Gross R. Untreated hypertension and the emergency department: a chance to intervene? Acad Emerg Med. 2008 Jun;15(6):529-36. doi: 10.1111/j.1553-2712.2008.00132.x
Demopoulos L, Polinsky M, Steele G, Mines D, Blum M, Caulfield M, Adamkovic A, Liu Q, Harler MB, Hahn C, Singh A. Reduced risk of cytomegalovirus infection in solid organ transplant recipients treated with sirolimus: a pooled analysis of clinical trials. Transplant Proc. 2008 Jun;40(5):1407-10. doi: 10.1016/j.transproceed.2008.03.084
Herrinton LJ, Liu L, Shoor S, Mines D. Risk of lymphoproliferative cancer among patients with severe rheumatoid arthritis, 1996-2002. Ann Rheum Dis. 2008 Apr;67(4):574-5. doi: 10.1136/ard.2007.075986
Mines D, Gu Y, Liu Q, Horne LN, Harrison MJ. Risk of active tuberculosis (TB) among biologic-naïve RA patients: retrospective cohort study in a US claims database. Presented at the 2008 Annual European Congress of Rheumatology; June 2008. Paris, France. [abstract] Ann Rheum Dis. 2008; 67(Supplement II):91.
Bongartz T, Warren FC, Mines D, Matteson EL, Abrams KR, Sutton AJ. Etanercept therapy in rheumatoid arthritis and the risk of malignancies. Presented at the 2008 Annual European Congress of Rheumatology; June 2008. Paris, France. [abstract] Ann Rheum Dis. 2008; 67(Supplement II):51.
Mines DI, Novelli LA, Yu H. Lymphoma risk in patients with rheumatoid arthritis who received 2 or more disease modifying anti-rheumatic drugs (DMARDs): a retrospective cohort study in the GPRD. Poster presented at the 21st ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2005. Nashville, TN. [abstract] Pharmacoepidemiol Drug Saf. 2005 Aug; 14(S2):S30.
Mines D, Hill D, Yu H, Novelli L. Prevalence of risk factors for suicide in patients prescribed venlafaxine, fluoxetine, and citalopram. Pharmacoepidemiol Drug Saf. 2005 Jun;14(6):367-72.